- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03828019
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial (ADVISE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Abstract from protocol: The uveitides are a collection of diseases characterized by intraocular inflammation. Collectively, they are the 5th leading cause of blindness in the US, and the estimated cost of treating them is similar to that of treating diabetic retinopathy. Non-infectious intermediate, posterior, and panuveitides have the highest rates of visual loss and typically are treated with oral corticosteroids and immunosuppression. The Multicenter Uveitis Steroid Treatment (MUST) Trial (a randomized, comparative effectiveness trial, which compared 2 treatment paradigms for these diseases, systemic therapy with corticosteroids and immunosuppression vs. regional therapy [the fluocinolone acetonide implant]), and Follow-up Study demonstrated the superiority of the systemic approach to the regional ocular approach in terms of long-term visual outcomes with essentially no increase in systemic side effects in the systemic group. One key to systemic therapy's success was the use of systemic immunosuppression in 88% of participants, coupled with tapering the prednisone to <7.5 mg/day, a relatively safe dose. Non-alklyating agents are typically the first choice and the most often used are azathioprine, methotrexate, mycophenolate, cyclosporine, and tacrolimus. The alkylating agents, cyclophosphamide and chlorambucil, are used less often because of concerns about potential increased malignancy risk. Data from the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study suggest that each of the conventional, non-alkylating agent immunosuppressive drugs is effective in controlling the inflammation while permitting tapering prednisone in ~40-55% of patients; hence combination therapy often is needed. Furthermore, minimizing the daily dose of prednisone is important, as the risk of cardiovascular disease and mortality increase with the cumulative dose of oral corticosteroids. In June 2016, the fully-human, anti-TNF-α monoclonal antibody, adalimumab, was approved by the US Food and Drug Administration (FDA) for the treatment of uveitis. Anti-TNF-α monoclonal antibody therapy has revolutionized the management of the rheumatic diseases largely due to its superior efficacy compared to conventional Disease Modifying Anti-Rheumatic Drugs. Data from VISUAL III, the extension of the two phase 3 trials that led to the FDA approval of adalimumab for the treatment of uveitis, suggest that adalimumab may be superior to conventional immunosuppression, as ~75% of participants had controlled inflammation with prednisone doses <5 mg/day. The ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial is a randomized, comparative effectiveness trial comparing adalimumab to conventional agent immunosuppression for patients with non-infectious, intermediate, posterior, and panuveitides. The primary outcome is the ability to successfully taper prednisone to <7.5 mg/day by 6 months after randomization while maintaining control of the inflammation. Secondary outcomes include prednisone discontinuation by 1 year, visual acuity, and complications of uveitis and its treatment.
ADVISE is being conducted under IND 132532. Adalimumab was FDA approved for the treatment of non-infectious intermediate, posterior, and panuveitides in adult patients in 2016 and in pediatric patients 2 years of age and older in 2018. In 2016, prior to the approval for pediatric patients, the FDA determined that use of adalimumab for the treatment of non-infectious intermediate, posterior, and panuveitides in adolescent patients in the ADVISE Trial does not increase risk for these patients as the drug is approved for treatment of pediatric patients for other indications. Although conventional immunosuppressive drugs are the standard approach and in widespread use, these drugs are not FDA approved for treatment of non-infectious intermediate, posterior, and panuveitides, and therefore an IND has been issued for this trial.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Janet T Holbrook, PhD MPH
- Phone Number: 443-287-5791
- Email: jholbro1@jhu.edu
Study Contact Backup
- Name: Elizabeth A Sugar, PhD
- Email: esugar2@jhu.edu
Study Locations
-
-
-
Sydney, Australia
- University of Sydney
-
-
Victoria
-
East Melbourne, Victoria, Australia
- Centre for Eye Research Australia
-
-
-
-
Quebec
-
Montréal, Quebec, Canada, H4A 3S5
- McGill University
-
-
-
-
-
Bradford, United Kingdom
- Bradford Teaching Hospital NHS Foundation Trust
-
Cambridge, United Kingdom, CB2 0QQ
- Cambridge University NHS Trust
-
Leicester, United Kingdom, LE1 5WW
- University Hospitals of Leicester
-
London, United Kingdom, EC1V 9EL
- Moorfields Eye Hospital NHS Foundation Trust
-
-
Birmingham
-
Edgbaston, Birmingham, United Kingdom, B15 2TH
- University Hospital Birmingham
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- Jules Stein Eye Institute, UCLA
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
Florida
-
Miami, Florida, United States, 33136
- Anne Bates Leach Eye Hospital, University of Miami Miller School of Medicine
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University
-
Bethesda, Maryland, United States, 20892
- National Eye Institute
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Ophthalmic Consultants of Boston
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48105
- University of Michigan Health System, Kellogg Eye Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- MidAtlantic Retina, Wills Eye Hospital
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Tennessee Retina
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Eye Institute
-
-
Texas
-
Bellaire, Texas, United States, 77401
- Retinal Consultants of Texas
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah, Moran Eye Center
-
-
Washington
-
Seattle, Washington, United States, 98104
- University of Washington, Medicine Eye Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria
- Age 13 years or older
- Weight 30 kg (66 lbs) or greater
- Active or recently active (≤ 60 days) non-infectious intermediate, posterior, or panuveitis
Prednisone indication meets one of the following:
- Active uveitis requiring one of the following i. Initiation of prednisone at dose greater than 7.5 mg/day ii. Increasing prednisone dose to greater than 7.5 mg/day iii. Currently receiving dose greater than 7.5 mg/day
- Inactive uveitis on current dose greater 7.5 mg/day
- Initiation or addition of an immunosuppressive drug (i.e., a conventional immunosuppressive drug or adalimumab) is indicated
- If currently receiving a conventional immunosuppressive drug, the drug and dose have been stable for at least 30 days
- Patient able and willing to self-administer subcutaneous injections or have a qualified person available to administer subcutaneous injections
- If posterior segment disease is present, ability to assess activity in at least one eye with uveitis
- Visual acuity of light perception or better in at least one eye with uveitis
Exclusion criteria
- Active tuberculosis or untreated latent tuberculosis (e.g., positive interferon-γ release assay [IGRA] test, such as Quantiferon-gold)
- Untreated active hepatitis B or C infection
Any of the following baseline lab values
- White blood count <3500 cells per microliter
- Platelets <100,000 per microliter
- Hematocrit <30%
- AST or ALT >1.5X upper limit normal value
- Serum creatinine >1.1X upper limit normal value
- Behçet disease
- Multiple sclerosis or other demyelinating disease
- For patients with anterior/intermediate or intermediate uveitis without systemic disease, abnormal magnetic resonance imaging (MRI) of the brain consistent with demyelinating disease
- Severe uncontrolled infection
- Receipt of a live vaccine within past 30 days
- Moderate to severe heart failure (NYHA class III/IV)
- Active malignancy
- Use of anti-TNF monoclonal antibody therapy within past 60 days
- History of adalimumab intolerance or ineffectiveness
- Hypersensitivity to any of the study treatments or their excipients
- Current treatment with an alkylating agent
- Current treatment with more than one immunosuppressive drug, not including oral corticosteroids
- Shorter-acting regional corticosteroids administered within the past 30 days in any eye(s) with uveitis
- Long-acting ocular corticosteroid implants, i.e., fluocinolone acetonide implant (e.g., Retisert®, YutiqTM, Iluvien®) placed within past 3 years unless uveitis is active in all eye(s) with an implant
- Systemic disease that is sufficiently active such that it dictates therapy with systemic corticosteroids or immunosuppressive agents at the time of enrollment
- Immunodeficiency disease for which immunosuppressive therapy would be contraindicated according to best medical judgment
- Pregnancy or lactation
For persons of child-bearing potential or impregnating potential, unwillingness to use appropriate birth control (abstinence, combination barrier and spermicide, hormonal, or intrauterine device) for the next 18 months or plans to become a biological parent within the next 18 months.
* In the UK, use of combination barrier and spermicide alone does not meet birth control requirements.
† UK female study participants must use highly effective methods of contraception.
UK male study participants must use condoms for at least 6 months after the end of study treatment and their female partners of child-bearing potential are recommended to use highly effective contraception for the same duration. In addition, male participants should not donate semen during therapy or for 6 months following discontinuation of study treatment.
- Medical problems or drug or alcohol dependence problems sufficient to prevent adherence to treatment and study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Adalimumab (ADA)
Adalimumab administered by subcutaneous injection at dosage and frequency specified below; total duration of treatment is 12 months. Adults (≥ 18 years of age) and adolescents ≥30 kg: 80 mg as initial dose; one week later by 40 mg then 40 mg every two weeks. Adolescents <30 kg: 40 mg as initial dose; one week later 20 mg then 20 mg every 2 weeks. |
Adalimumab is a fully-human monoclonal antibody to TNF-α, which is approved by the U.S. FDA for the treatment of non-infectious intermediate, posterior, and panuveitides in adults and children 2 years of age and older.
Other Names:
|
Active Comparator: Conventional immunosuppression (CON)
Conventional immunosuppressive agent selected by study ophthalmologist at dose and frequency specified below;12 month treatment duration. Azathioprine: initially 2 mg/kg/day; max dose 200 mg/day. Methotrexate initially 15mg/wk; max dose 25 mg/wk. Mycophenolate initially 1 gm BID; max dose1.5 gm BID. Cyclosporine (Sandimmune - dose 2.5 mg/kg BID and Neoral dose 2 mg/kg BID. Tacrolimus initially 1 mg BID; max dose 3 mg BID. |
The study ophthalmologist will select amongst the permissible drugs (methotrexate, mycophenolate mofetil or azathioprine for antimetabolites; cyclosporine or tacrolimus for calcineurin inhibitors) taking into account the side effect profile of each drug with respect to subject's clinical situation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Corticosteroid-sparing treatment success within the first 6 months after randomization
Time Frame: 6 months
|
Corticosteroid-sparing success is defined as achieving inactive uveitis for two consecutive visits >= 28 days apart while on <= 7.5 mg/day of corticosteroids.
Uveitis status (active vs inactive) is determined by the study ophthalmologist after reviewing the eye exam and imaging.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Corticosteroid-sparing treatment success within the first 12 months after randomization
Time Frame: 12 months
|
Corticosteroid-sparing success is defined as achieving inactive uveitis for two consecutive visits >= 28 days apart while on <= 7.5 mg/day of corticosteroids.
Uveitis status (active vs inactive) is determined by the study ophthalmologist after reviewing the eye exam and imaging.
|
12 months
|
Prednisone discontinuation success
Time Frame: 12 months
|
Prednisone discontinuation success is defined as achieving inactive uveitis for two consecutive visits >= 28 days apart after discontinuing corticosteroids.
Uveitis status (active vs inactive) is determined by the study ophthalmologist after reviewing the eye exam and imaging.
|
12 months
|
Prednisone exposure
Time Frame: 12 months
|
E.g., cumulative prednisone dose and/or mean prednisone dose
|
12 months
|
Best corrected visual acuity
Time Frame: 12 months
|
Best corrected visual acuity measured after a standardized refraction using logarithmic visual acuity charts
|
12 months
|
Infections
Time Frame: 12 months
|
Incidence of infections over 12 months of follow-up
|
12 months
|
Systemic adverse events
Time Frame: 12 months
|
Systemic adverse events over 12 months of follow-up
|
12 months
|
Macular edema
Time Frame: 12 months
|
Macular edema over 12 months of follow-up
|
12 months
|
Health utility
Time Frame: 12 months
|
Health utility will be measured using the EQ-5D
|
12 months
|
Generic health-related quality of life
Time Frame: 12 months
|
Generic health-related quality of life will be measured using the SF-36
|
12 months
|
Vision-related quality of life
Time Frame: 12 months
|
Vision-related quality of life will be measured using the NEI-VFQ-25
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Douglas A Jabs, MD MBA, CCTand Evidence Synthesis, JHU, Bloomberg School of Public Health
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Uveal Diseases
- Uveitis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Antifungal Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Tumor Necrosis Factor Inhibitors
- Calcineurin Inhibitors
- Adalimumab
- Methotrexate
- Azathioprine
- Tacrolimus
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- 9196 (CTEP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uveitis
-
Priovant Therapeutics, Inc.Active, not recruitingNon-infectious Intermediate Uveitis | Non-infectious Posterior Uveitis | Non-infectious Pan UveitisUnited States
-
University of NebraskaUnknownPosterior Uveitis | Intermediate Uveitis | Pan-uveitisUnited States
-
Stanford UniversitySanten Inc.WithdrawnPanuveitis | Uveitis | Posterior Uveitis | Intermediate UveitisUnited States
-
EyePoint Pharmaceuticals, Inc.CompletedPanuveitis | Posterior Uveitis | Intermediate UveitisIndia
-
Johns Hopkins UniversityMacuSight, Inc.CompletedPanuveitis | Uveitis | Posterior Uveitis | Intermediate UveitisUnited States
-
CHU de Quebec-Universite LavalCompletedIntermediate Uveitis | Anterior UveitisCanada
-
Novartis PharmaceuticalsCompletedNon-infectious Intermediate Uveitis | Non-infectious Posterior Uveitis | Non-infectious PanuveitisUnited States, United Kingdom
-
The New York Eye & Ear InfirmaryUnknownPanuveitis | Uveitis | Posterior Uveitis | Anterior UveitisUnited States
-
Duke UniversityCompletedPosterior Uveitis | Intermediate UveitisUnited States
-
AllerganCompletedPosterior Uveitis | Intermediate UveitisFrance, United Kingdom, United States, Spain, Poland, India, South Africa, Korea, Republic of, Canada, Czech Republic, Australia, Germany, Israel, Switzerland, Portugal, Austria, Brazil, Greece
Clinical Trials on Adalimumab (ADA)
-
Rehab WeridaCompleted
-
Ada Health GmbHBabes-Bolyai University; Botnar FoundationCompletedMental Health Issues | Gastrointestinal Issues | Respiratory Issues | Cardiovascular Issues | Genitourinary Issues | Musculoskeletal Issues | ENT Issues | Eye Issues | Neurologic IssuesRomania
-
Ada Health GmbHMuhimbili University of Health and Allied SciencesActive, not recruitingNeurological Conditions | Mental Health Conditions | Abdominal Pain/Gastrointestinal Issues | Lower Respiratory System Conditions | Upper Respiratory System Conditions | Ophthalmology Conditions | Orthopedic Conditions | Cardiovascular System Conditions | Genitourinary System Conditions | ENT Conditions | Dermatology Conditions and other conditionsTanzania
-
Hospital de Clinicas de Porto AlegreTerminated
-
Siel BleuInstitut National de la Santé Et de la Recherche Médicale, FranceRecruitingQuality of Life | Breast CancerFrance
-
University of Massachusetts, WorcesterCompletedLow-GI Dietary Education | ADA Dietary EducationUnited States
-
UCB Pharma SAParexelCompletedRheumatoid ArthritisRomania, United States, Australia, Austria, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Ireland, Italy, Mexico, Monaco, Poland, Portugal, Spain, Switzerland, United Kingdom
-
Adapt Produtos Oftalmológicos Ltda.Unknown
-
Hadassah Medical OrganizationCompletedObese Type 2 Diabetic Patients